Could GLP-1 Weight-Loss Drugs Also Slow Down Ageing?

GLP-1 receptor agonists — the class of drugs that includes well-known names like semaglutide (sold as Ozempic and Wegovy) and liraglutide — have taken the world by storm as treatments for type 2 diabetes and obesity. But researchers are now asking a bigger question: could these medications also slow down the ageing process?

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut that stimulates insulin release and suppresses appetite. The drugs mimic this hormone, helping patients manage blood sugar and lose weight. Their popularity has surged globally, including in Mauritius, where diabetes and obesity are among the leading public health challenges.

Beyond weight loss, clinical studies have shown that GLP-1 drugs reduce the risk of heart attacks, strokes, and kidney disease — conditions strongly associated with ageing. This has led scientists to explore whether the drugs may be acting on deeper biological mechanisms linked to how the body ages at a cellular level.

Some researchers believe GLP-1 drugs may reduce chronic low-grade inflammation — sometimes called "inflammaging" — which is considered a key driver of age-related diseases. There is also early evidence that these medications may influence cellular senescence, the process by which damaged cells stop dividing but remain in the body and release harmful signals to surrounding tissue.

Animal studies have shown promising results, with GLP-1 treatment linked to longer lifespans in some models. However, scientists caution that findings in mice do not always translate to humans, and long-term human data specifically focused on ageing outcomes is still limited.

Several clinical trials are now underway globally to examine whether GLP-1 drugs can reduce the incidence of age-related conditions beyond diabetes and heart disease — including dementia, cancer, and Parkinson's disease. Results from these studies are expected over the coming years.

For Mauritius, where the population is ageing and the prevalence of non-communicable diseases is among the highest in sub-Saharan Africa, the implications could be significant. The country's public health system, managed through the Ministry of Health and Wellness, already provides certain diabetes medications free of charge, though GLP-1 injectable drugs remain largely in the private sector due to their high cost.

What this means: GLP-1 drugs are not yet proven anti-ageing treatments, and no health authority has approved them for that purpose. But the emerging science is generating serious interest in the medical community. For Mauritians managing diabetes or obesity, these drugs are already accessible through private clinics and pharmacies — though cost and availability can vary. Anyone considering GLP-1 therapy should consult a doctor, as these medications require a prescription and careful medical supervision.

The broader question of whether a drug taken by millions worldwide could meaningfully extend healthy life expectancy remains open — but it is no longer considered a far-fetched one.

Source: Le Defi Media